{"database": "lobbying", "table": "lobbying_activities", "rows": [[2310162, "e857a1fd-989b-4cd4-b0a6-589f7fe82f75", "Q2", "ASSOCIATION FOR ACCESSIBLE MEDICINES", 16032, "ASSOCIATION FOR ACCESSIBLE MEDICINES", 2019, "second_quarter", "PHA", "Implementation of Food and Drug Administration Reauthorization Act (FDARA).\nGeneric Drug User Fee Amendments (GDUFA).\nBiosimilar User Fee Act (BsUFA).\nLabeling of Generic Drugs.\nDrug Compounding.\nDrug Shortages.\nBiosimilars Naming.\nBiosimilars Insulin.\nPass Through Payments for Biosimilars.\nPrescription Drug Costs.\nAmerican Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.\nProposed Anti-Kickback Statute (AKS) Rebates.\nFDA Citizen Petitions.\nH.R.985: FAST Generics Act of 2019.\nH.R.1506: FAIR Generics Act.\nH.R.1503: Orange Book Transparency Act of 2019.\nH.R.1520: Purple Book Continuity Act of 2019.\nS.61: Safe and Affordable Drugs from Canada Act of 2019.\nS.64: Preserve Access to Affordable Generics and Biosimilars Act.\nS.1416: Affordable Prescriptions for Patients Act of 2019.\nS.1224: Stop STALLING Act.\nH.R.447/S.97: Affordable and Safe Prescription Drug Importation Act.\nS.124: Freedom to Compete Act.\nH.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.\nH.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.\nH.R.465/S.102: Prescription Drug Price Relief Act of 2019.\nH.R.1093/S. 378: Stop Price Gouging Act.\nS.474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019.\nS.475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019.\nS.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019.\nS.440: Preserving Access to Cost Effective Drugs (PACED) Act.\nS.1895: Lower Health Care Costs Act.\nH.R.965/S.340: CREATES Act of 2019.\nPublic Law 115-123: Bipartisan Budget Act of 2018.\nRisk Evaluation and Mitigation Strategies (REMS).\nPharmaceutical Exclusivity.\nBiologic Exclusivity.\nH.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act.\nS.659: Biologic Patent Transparency Act.\nBiologics Price Competition and Innovation Act (BPCIA).\nPublic Law 115-52: FDA Reauthorization Act of 2017.", "Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Congressional Budget Office (CBO),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Patent & Trademark Office (PTO),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)", null, 1100000, 0, 0, "2019-07-18T13:49:22.430000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2310162"], "units": {}, "query_ms": 3.904643002897501, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}